MX9302951A - Composicion farmaceutica para tratar la hiperproliferacion celular. - Google Patents

Composicion farmaceutica para tratar la hiperproliferacion celular.

Info

Publication number
MX9302951A
MX9302951A MX9302951A MX9302951A MX9302951A MX 9302951 A MX9302951 A MX 9302951A MX 9302951 A MX9302951 A MX 9302951A MX 9302951 A MX9302951 A MX 9302951A MX 9302951 A MX9302951 A MX 9302951A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
cell hyperproliferation
treat cell
hyperproliferation
treat
Prior art date
Application number
MX9302951A
Other languages
English (en)
Inventor
Ben Y Tseng
Kevin D Cooper
Craig Hammerberg
Kameron W Maxwell
Original Assignee
Genta Inc
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genta Inc, Univ Michigan filed Critical Genta Inc
Publication of MX9302951A publication Critical patent/MX9302951A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Se proporcionan métodos para tratar trastornos o condiciones caracterizadas por hiperproliferación celular utilizando compuestos inhibidores de interleucina-1 y compuestos útiles en los métodos descritos.
MX9302951A 1992-05-22 1993-05-20 Composicion farmaceutica para tratar la hiperproliferacion celular. MX9302951A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88773492A 1992-05-22 1992-05-22

Publications (1)

Publication Number Publication Date
MX9302951A true MX9302951A (es) 1994-07-29

Family

ID=25391751

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9302951A MX9302951A (es) 1992-05-22 1993-05-20 Composicion farmaceutica para tratar la hiperproliferacion celular.

Country Status (9)

Country Link
EP (1) EP0644765A4 (es)
JP (1) JPH07508977A (es)
KR (1) KR950701528A (es)
AU (1) AU4388993A (es)
CA (1) CA2136349A1 (es)
IL (1) IL105741A0 (es)
MX (1) MX9302951A (es)
NZ (1) NZ253509A (es)
WO (1) WO1993024134A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
GB9405021D0 (en) * 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
ATE428785T1 (de) 1996-03-01 2009-05-15 Euroscreen Sa Aktive und inactive cc-chemokinrezeptoren und nukleinsäuremoleküle, die für diesen rezeptor kodieren
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
IL133913A0 (en) * 1997-07-10 2001-04-30 Therakos Inc Treatment of inflammatory disorders of the bowel and urinary bladder
WO2004100987A2 (en) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
US7960355B2 (en) 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein
US7897582B2 (en) 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
WO2006084145A2 (en) * 2005-02-02 2006-08-10 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to reduce c-reactive protein
GB0607189D0 (en) * 2006-04-10 2006-05-17 Polybiomed Ltd interleukin IL 1ra composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0353290A4 (en) * 1988-01-21 1990-09-05 Chemex Pharmaceuticals, Inc. Selective inhibition of gene expression by photoactivatable oligonucleotides
EP0527790A4 (en) * 1990-04-09 1993-09-15 The American National Red Cross Rejuvenation compositions and methods for their use
US5135917A (en) * 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
IL101978A0 (en) * 1991-05-31 1992-12-30 Genta Inc Neutral oligomers capable of being delivered transdermally and across mucous membranes
HU220098B (hu) * 1991-08-30 2001-10-28 Vertex Pharmaceuticals Incorporated Interleukin-1 béta proteáz enzim, és interleukin-1 béta proteáz inhibitorok

Also Published As

Publication number Publication date
EP0644765A4 (en) 1997-02-26
AU4388993A (en) 1993-12-30
KR950701528A (ko) 1995-04-28
EP0644765A1 (en) 1995-03-29
WO1993024134A1 (en) 1993-12-09
NZ253509A (en) 1999-09-29
JPH07508977A (ja) 1995-10-05
IL105741A0 (en) 1993-09-22
CA2136349A1 (en) 1993-12-09

Similar Documents

Publication Publication Date Title
ES2194106T3 (es) .ompuestos de imidazol
WO1993021942A3 (en) Use of mmp inhibitors
MX9300766A (es) Piridonas sustituidas por sulfonilbencilo, procedimiento para su obtencion y medicamentos que las contienen.
FI953748A (fi) Yhdisteitä, joilla on sekä voimakas kalsium antagonisti- että antioksidanttiaktiivisuus sekä niiden käyttö solua suojaavina aineina
ES2089687T3 (es) 4-fenil-piridonas y 4-fenil-2-alcoxipiridinas sustituidas como inhibidores de la hmg-coa-reductasa.
ES2196082T3 (es) Analagos del factor de crecimiento de queratinocitos.
BR8904519A (pt) Composicao fungicida,processos para preparar compostos fungicidas e para preparar compostos de benzoilacetonitrila
MX9302951A (es) Composicion farmaceutica para tratar la hiperproliferacion celular.
MX9203092A (es) Composicion anestesica y metodo para su uso.
ES281454Y (es) Disposicion para la conservacion de plantas en grandes despachos, restaurantes, bancos o similares
AR240975A1 (es) Composicion para tratamiento de plantas
ES505321A0 (es) Procedimiento para la desintegracion de derivados de 6-amino-5-triacina,contenidos en aguas residuales
ES2032922T3 (es) Empleo de los paf-aceter antagonicos para la fabricacion de un medicamento y procedimiento para determinar la eficacia de los mismos.
IT7823336A0 (it) Composizione adatta alla riduzione del tenore di fenilalanina e metodo impiegante la stessa.
BR8803768A (pt) Composicao odorante,processo para producao de compostos e uso dos ditos compostos
ES525297A0 (es) Procedimiento para la obtencion de derivados de terc.-butanol sustituidos
BR8801117A (pt) Composto,processo para sua obtencao,composicao para o combate de doencas em plantas,utilizacao e cultura
ATE40116T1 (de) 1-acyl-3-pyridylmethylguanidine und deren verwendung als antihypertensiva.
ES518877A0 (es) Perfeccionamientos en las plantas para la incineracion de basuras.
ITRM920305A1 (it) Composizione farmaceutica per il trattamento dello shock, particolarmente dello shock cardiogeno e dello shock settico.
ES542274A0 (es) Procedimiento y disposicion para el tratamiento de papelote
ES543582A0 (es) Perfeccionamientos en los batanes para el tratamiento de pieles y similares
DE3583337D1 (de) Zusammensetzung zur behandlung von haemorroiden.
ES521091A0 (es) Mejoras en el objeto de la patente principal no 513.956 por procedimiento para la carbonilacion de olefinas y esteres organicos.
ES264767Y (es) Lama perfeccionada para puertas enrollables.